Anika Therapeutics, Inc.ANIKNASDAQ
Loading
Gross Profit Growth Recovery in ProgressRecovering
Percentile Rank82
3Y CAGR+57.2%
Year-over-Year Change
Year-over-year gross profit growth rate
3Y CAGR
+57.2%/yr
vs +93.4%/yr prior
Acceleration
-36.2pp
Decelerating
Percentile
P82
Within normal range
vs 3Y Ago
3.9x
Strong expansion
Streak
3 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 23.07% |
| Q3 2025 | 8.50% |
| Q2 2025 | -2.17% |
| Q1 2025 | -34.94% |
| Q4 2024 | 1467.01% |
| Q3 2024 | -92.97% |
| Q2 2024 | -16.81% |
| Q1 2024 | -6.46% |
| Q4 2023 | 5.55% |
| Q3 2023 | -13.90% |
| Q2 2023 | 26.83% |
| Q1 2023 | -5.34% |
| Q4 2022 | 5.94% |
| Q3 2022 | -8.38% |
| Q2 2022 | 14.02% |
| Q1 2022 | 20.24% |
| Q4 2021 | -21.24% |
| Q3 2021 | 10.62% |
| Q2 2021 | -0.77% |
| Q1 2021 | 25.26% |
| Q4 2020 | -3.45% |
| Q3 2020 | 26.20% |
| Q2 2020 | -35.17% |
| Q1 2020 | 0.35% |
| Q4 2019 | -11.05% |
| Q3 2019 | 0.70% |
| Q2 2019 | 35.44% |
| Q1 2019 | -12.74% |
| Q4 2018 | 7.84% |
| Q3 2018 | -17.37% |
| Q2 2018 | 66.90% |
| Q1 2018 | -35.09% |
| Q4 2017 | -1.25% |
| Q3 2017 | -22.89% |
| Q2 2017 | 56.89% |
| Q1 2017 | -18.33% |
| Q4 2016 | 1.90% |
| Q3 2016 | 1.34% |
| Q2 2016 | 21.70% |
| Q1 2016 | -31.48% |